Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV43GY)

• Drug Name: CEP-5104 Drug Info
• Synonyms: C25H22N2O3; 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-5104; CHEMBL460989; SCHEMBL3264941; BDBM24947; ZINC40861910; 5-oxo dihydronaphthylcarbazole analogue, 14; X7364

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 23378546
  TTD Drug ID: DMV43GY

Molecule-Related Drug Atlas

Drug(s) Targeting Tropomyosin-related kinase A (TrkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small cell lung cancer	2C25	Approved	[2]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
MIM-D3	DMZHN5B	Alzheimer disease	8A20	Phase 3	[4]
SNA-120	DMPN314	Plaque psoriasis	EA90.0	Phase 2	[5]
CT 327	DMQXL1T	Plaque psoriasis	EA90.0	Phase 2	[6]
TPX-0005	DM9FB2T	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
ONO-7579	DMXLPYE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[9]
DS-6051	DM0RD4F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]

Drug(s) Targeting Mixed lineage kinase 3 (MAP3K11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
URMC-099	DMCJXWK	Discovery agent	N.A.	Investigative	[11]
CEP-6331	DMNXBTD	Discovery agent	N.A.	Investigative	[1]
CEP1349	DMOAZX5	Discovery agent	N.A.	Investigative	[12]
PMID24044867C8	DML4KMP	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting LCK tyrosine protein kinase (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[13]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[15]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[16]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[16]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[17]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[16]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[18]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[19]

Drug(s) Targeting Fyn tyrosine protein kinase (FYN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[13]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[21]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[22]
CEP-6331	DMNXBTD	Discovery agent	N.A.	Investigative	[1]
JNJ-10198409	DM9GDP5	Discovery agent	N.A.	Investigative	[23]
1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	DMD7WNV	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting Mixed lineage kinase 1 (MAP3K9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CEP1347	DMXCD69	Asthma	CA23	Phase 2/3	[12]
URMC-099	DMCJXWK	Discovery agent	N.A.	Investigative	[11]
CEP-6331	DMNXBTD	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[25]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[26]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[27]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[28]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[29]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[30]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[31]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[32]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[33]

Drug(s) Targeting Mixed lineage kinase 2 (MAP3K10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
URMC-099	DMCJXWK	Discovery agent	N.A.	Investigative	[11]
CEP-6331	DMNXBTD	Discovery agent	N.A.	Investigative	[1]
CEP1348	DMA7JO4	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fyn tyrosine protein kinase (FYN)	TT2B9KF	FYN_HUMAN	Inhibitor	[1]
LCK tyrosine protein kinase (LCK)	TT860QF	LCK_HUMAN	Inhibitor	[1]
Mixed lineage kinase 1 (MAP3K9)	TTUNSIX	M3K9_HUMAN	Inhibitor	[1]
Mixed lineage kinase 2 (MAP3K10)	TT9FN4J	M3K10_HUMAN	Inhibitor	[1]
Mixed lineage kinase 3 (MAP3K11)	TTETX6Q	M3K11_HUMAN	Inhibitor	[1]
Tropomyosin-related kinase A (TrkA)	TTTDVOJ	NTRK1_HUMAN	Inhibitor	[1]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[1]

References

• [1] Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [9] National Cancer Institute Drug Dictionary (drug id 747694).
• [10] National Cancer Institute Drug Dictionary (drug id 766123).
• [11] Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
• [12] Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
• [13] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [14] National Cancer Institute Drug Dictionary (drug id 596693).
• [15] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [16] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [17] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [18] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [19] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [20] National Cancer Institute Drug Dictionary (drug id 596693).
• [21] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [22] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [23] (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
• [24] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [25] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [26] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [27] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [28] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [29] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [30] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [31] Clinical pipeline report, company report or official report of Exelixis (2011).
• [32] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [33] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.